About the Company
Epizyme, Inc. is a fully integrated, commercial-stage biopharmaceutical company committed to its mission of rewriting treatment for cancer and other serious diseases through novel epigenetic medicines. In addition to an active research and discovery pipeline, Epizyme has one U.S. FDA approved product, TAZVERIK® (tazemetostat), for the treatment of adults and pediatric patients aged 16 years and older with metastatic or locally advanced epithelioid sarcoma (ES) who are not eligible for complete resection; adult patients with relapsed or refractory follicular lymphoma (FL) whose tumors are positive for an EZH2 mutation as detected by an FDA-approved test and who have received at least two prior systemic therapies; and adult patients with relapsed or refractory follicular lymphoma who have no satisfactory alternative treatment options. These indications are approved under accelerated approval based on overall response rate and duration of response. Continued approval for these indications may be contingent upon verification and description of clinical benefit in confirmatory trials. The Company is also exploring the treatment potential of tazemetostat in investigational clinical trials in other solid tumors and hematological malignancies, as a monotherapy and combination therapy in both relapsed and front-line disease settings. By focusing on the genetic drivers of disease, Epizyme seeks to match medicines with the patients who need them..
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest $EPZM News
Ipsen beefs up in oncology, buying US biopharma Epizyme
The revamp of French drugmaker Ipsen has continued with a takeover agreement for US counterpart Epizyme and its cancer therapy Tazverik, in a deal valued at a little under $250 million. Ipsen is ...
MPM Asset Management Investors BV4 LLC's Net Worth
Who is MPM Asset Management Investors BV4 LLC? MPM Asset Management Investors BV4 LLC has an estimated net worth of $148 Million. This is based on reported shares across multiple companies, which ...
Sweet Baby Inc. Doesn’t Do What Some Gamers Think It Does
Sweet Baby Inc. is not the largest narrative design company in the games industry. Nor is it solely responsible for the characters and stories in recent high-profile releases like Alan Wake 2 ...
Did The Texas ESG Ban Have Any Bite?
Opinions expressed by Forbes Contributors are their own. I am the Kester and Brynes Professor at Columbia Business School and a Chazen Senior Scholar at the Jerome A. Chazen Institute for Global ...
MPM BioVentures IV GP LLC's Net Worth
Who is MPM BioVentures IV GP LLC? MPM BioVentures IV GP LLC has an estimated net worth of $148 Million. This is based on reported shares across multiple companies, which include Radius Health, Inc ...
Beasley Broadcast Group, Inc. (BBGI)
Beasley Broadcast Group, Inc. ( NASDAQ:BBGI ) shareholders are probably feeling a little disappointed, since its shares... Simply Wall St. Beasley Broadcast Group Full Year 2023 Earnings ...
Welcome to Inc.'s Directory of B2B Excellence
They all made it through Inc.'s proprietary vetting process, based in part on testimonials from other clients. As any entrepreneur knows, the right partnership can make all the difference.
STIHL Inc.
This company has paid to receive expanded profile features. About STIHL Inc. Virginia-based STIHL Inc. is the U.S. affiliate for the global STIHL group and the manufacturer of the number one ...
Snap Inc Class A
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Apple Inc.
No significant news for in the past two years. Key Stock Data P/E Ratio (TTM) The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing ...
About Inc.com | Everything You Need to Know to Grow and Start Your Business
Inc. is the voice of the American entrepreneur. We inspire, inform, and document the most fascinating people in business: the risk-takers, the innovators, and the ultra-driven go-getters that ...
Snap Inc.
The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...
Loading the latest forecasts...